Download Files:

Calmidazolium (chloride)

$72$275

Products Details

Product Description

– Calmidazolium chloride (R 24571) is a calmodulin antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC50s of 0.15 and 0.35 μM, respectively[1]. Also in anti-cancer research[2]. Calmidazolium binds to calmodulin with a Kd of 3 nM.

Web ID

– HY-103319

Storage Temperature

– -20°C (Powder, sealed storage, away from moisture)

Shipping

– Blue Ice

Applications

– Cancer-Kinase/protease

Molecular Formula

– C31H23Cl7N2O

References

– [1]Gietzen K, et al. Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem J. 1983 Dec 15;216(3):611-6.|[2]Lee J, et al. Calmidazolium chloride inhibits growth of murine embryonal carcinoma cells, a model of cancer stem-like cells. Toxicol In Vitro. 2016 Sep;35:86-92.|[3]Budu A, et al. Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.

CAS Number

– 57265-65-3

Molecular Weight

– 687.70

Compound Purity

– 99.69

SMILES

– ClC1=CC=C(COC(C2=CC=C(Cl)C=C2Cl)CN3C=C[N+](C(C4=CC=C(Cl)C=C4)C5=CC=C(Cl)C=C5)=C3)C(Cl)=C1.[Cl-]

Clinical Information

– No Development Reported

Research Area

– Cancer; Neurological Disease

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– Autophagy;Calmodulin

Pathway

– Autophagy;Membrane Transporter/Ion Channel

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.